Michael Meyring

EMD 1214063 and EMD 1204831 Constitute a New Class of Potent and Highly Selective c-Met Inhibitors

Friedhelm Bladt, Bettina Faden, Manja Friese‐Hamim et al. · Clinical Cancer Research · 2013 · 138 citations · Full text

Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases

Richard D. Caldwell, Hui Qiu, Ben Askew et al. · Journal of Medicinal Chemistry · 2019 · 136 citations · Full text

Novel Therapy, Medicine, Tyrosine Kinase +14

Simultaneous separation and enantioseparation of thalidomide and its hydroxylated metabolites using high-performance liquid chromatography in common-size columns, capillary liquid chromatography and nonaqueous capillary electrochromatography

Michael Meyring, Bezhan Chankvetadze, Gottfried Blaschke · Journal of Chromatography A · 2000 · 89 citations

Biochemistry, Separation Science, Common-size Columns +10

Identification and optimization of pyridazinones as potent and selective c-Met kinase inhibitors

Dieter Dorsch, Oliver Schadt, Frank Stieber et al. · Bioorganic & Medicinal Chemistry Letters · 2015 · 88 citations · Full text

Medicinal Chemistry, Biochemistry, Medicine +7

In Vitro Biotransformation of (<i>R</i>)<i>-</i>and (<i>S</i>)<i>-</i>Thalidomide:  Application of Circular Dichroism Spectroscopy to the Stereochemical Characterization of the Hydroxylated Metabolites

Michael Meyring, Jörg Mühlbacher, Kim Messer et al. · Analytical Chemistry · 2002 · 50 citations